OPTICAL NETWORK UNIT, OPTICAL ACCESS NETWORK AND A METHOD FOR EXCHANGING INFORMATION
    72.
    发明公开
    OPTICAL NETWORK UNIT, OPTICAL ACCESS NETWORK AND A METHOD FOR EXCHANGING INFORMATION 审中-公开
    光网络单元用于信息交流的光纤接入网络和方法

    公开(公告)号:EP2586146A2

    公开(公告)日:2013-05-01

    申请号:EP11797715.7

    申请日:2011-06-22

    IPC分类号: H04J14/02

    摘要: An Optical Access Network, a Optical Network Unit (ONU) and various methods for exchanging information are provided. The method may include : receiving, by the ONU, a pilot signal and downstream information signals; wherein the pilot signal is received at a pilot frequency slot and the downstream information signals are received at a downstream information frequency slot; wherein the ONU is allocated with a spectral slice that comprises the pilot frequency slot, the downstream information frequency slot, a guard frequency slot and an upstream information frequency slot; wherein at least one other spectral slice is allocated for exchanging information with at least one other group of ONUs; splitting the downstream information signals to downstream information signals portions; splitting the pilot signals to pilot signals portions; detecting downstream information, in response to at least a first portion of downstream information signals; modulating a portion of the pilot signal by upstream information signals to provide upstream information signals that are within the upstream information frequency slot; modulating a second portion of the downstream information signals by the upstream information signals to provide upstream secondary signals that are outside the pilot frequency slot, the downstream information frequency slot and the upstream information frequency slot; and upstream transmitting the upstream information signals and the upstream secondary signals.

    ORGANISM WITH ALTERED CAROTENOID CONTENT AND METHOD OF PRODUCING SAME
    74.
    发明公开
    ORGANISM WITH ALTERED CAROTENOID CONTENT AND METHOD OF PRODUCING SAME 有权
    有机质麻醉剂改性剂CARETINOIDGEHALT UND HERSTELLUNGSVERFAHRENDAFÜR

    公开(公告)号:EP2545177A1

    公开(公告)日:2013-01-16

    申请号:EP11714114.3

    申请日:2011-03-09

    IPC分类号: C12N15/82 C07K14/415 A01H5/00

    CPC分类号: C12N15/825 C07K14/415

    摘要: The present invention relates to means and methods for modifying the expression of a component in the carotenoid biosynthetic pathway to modify the production of carotenoid towards accumulation of at least one of phytoene, phytofluene, zeta carotene or combinations thereof. The present invention further relates to genetically altered organisms having elevated content of these carotenoids. The present invention further relates to genetically altered organisms having elevated content of these carotenoids, particularly in chromoplast-containing cells.

    摘要翻译: 本发明涉及用于修饰类胡萝卜素生物合成途径中组分表达的方法和方法,以修饰类胡萝卜素向至少一种柚子,植物荧光素,eta胡萝卜素或其组合的积累产生。 本发明还涉及具有升高的这些类胡萝卜素含量的遗传改变的生物。 本发明还涉及具有升高的这些类胡萝卜素含量的遗传改变的生物,特别是在含有色素体的细胞中。

    LIPOSOMES COMPRISING AMPHIPATHIC DRUGS AND METHOD FOR THEIR PREPARATION
    75.
    发明公开
    LIPOSOMES COMPRISING AMPHIPATHIC DRUGS AND METHOD FOR THEIR PREPARATION 审中-公开
    根据上述制造两性剂和脂质体过程

    公开(公告)号:EP2531175A2

    公开(公告)日:2012-12-12

    申请号:EP11706936.9

    申请日:2011-02-01

    摘要: The present invention provides a liposome having co-encapsulated in its intraliposomal aqueous core at least two amphipathic drugs, the liposomes being characterized by one of the following: the amphipathic drugs are co-encapsulated at a pre-determined ratio; the liposome comprises one or a combination of liposome forming lipids have a solid ordered to liquid disordered phase transition temperature above 37°C; each of the amphipathic drugs exhibit a liposomal profile that corresponds to the profile of each drug when encapsulated as a single drug in the same liposome; and the liposome is absent of one or both of a transition metal and a ionophore. The invention also provides a method for preparing such liposomes. This method, taken together with the features of the liposomal composition, provides high loading and long term stability of the resulting co-encapsulated liposomal formulation.